Compare CDLX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | GDTC |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.9M |
| IPO Year | 2018 | 2021 |
| Metric | CDLX | GDTC |
|---|---|---|
| Price | $1.27 | $0.80 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.43 | N/A |
| AVG Volume (30 Days) | ★ 61.1K | 11.6K |
| Earning Date | 11-05-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.68 |
| 52 Week High | $6.40 | $2.29 |
| Indicator | CDLX | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 27.28 | 34.42 |
| Support Level | $0.85 | $0.73 |
| Resistance Level | $2.32 | $1.07 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 2.83 | 0.00 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.